Literature DB >> 2177675

A nonlinear three-compartment model for the administration of 2',3'-dideoxycytidine by using red blood cells as bioreactors.

F Solimano1, G I Bischi, M Bianchi, L Rossi, M Magnani.   

Abstract

A non-linear three-compartment model is proposed to describe a new strategy for the administration of 2',3'-dideoxycytidine (ddCyd) in the treatment of HIV infections. The drug is injected after having been encapsulated in a non-diffusible form (ddCMP) into erythrocytes. Numerical solutions show that by this treatment the highest ddCyd blood concentration is strongly reduced and in turn its toxicity, while long-lasting therapeutic effect is assured. The model is compared with experimental data in vitro.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2177675     DOI： 10.1007/BF02460809

Source DB:  PubMed          Journal:  Bull Math Biol        ISSN： 0092-8240            Impact factor:   1.758


  6 in total

1.  2',3'-dideoxycytidine permeation of the human erythrocyte membrane.

Authors:  M Magnani; M Bianchi; L Rossi; V Stocchi
Journal:  Biochem Int       Date:  1989-08

Review 2.  Strategies for antiviral therapy in AIDS.

Authors:  H Mitsuya; S Broder
Journal:  Nature       Date:  1987 Feb 26-Mar 4       Impact factor: 49.962

3.  Reversed-phase liquid chromatographic determination of 2',3'-dideoxycytidine in human blood samples.

Authors:  M Magnani; L Rossi; M Bianchi; L Cucchiarini; V Stocchi
Journal:  J Chromatogr       Date:  1989-06-30

4.  Human red blood cells as bioreactors for the release of 2',3'-dideoxycytidine, an inhibitor of HIV infectivity.

Authors:  M Magnani; M Bianchi; L Rossi; V Stocchi
Journal:  Biochem Biophys Res Commun       Date:  1989-10-16       Impact factor: 3.575

5.  Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.

Authors:  H Mitsuya; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

6.  Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

Authors:  R Yarchoan; C F Perno; R V Thomas; R W Klecker; J P Allain; R J Wills; N McAtee; M A Fischl; R Dubinsky; M C McNeely
Journal:  Lancet       Date:  1988-01-16       Impact factor: 79.321
  6 in total
  1 in total

1.  An optimal time control problem for the administration of 2',3'-dideoxycytidine by using red blood cells as bioreactors.

Authors:  E Beretta; F Solimano
Journal:  Bull Math Biol       Date:  1993       Impact factor: 1.758
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.